

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/810,793	03/25/2004	Zhijian J. Chen	MPI96-031CP1DV1CPACN2M 1019	
30405 7	7590 11/30/2005		EXAMINER	
MILLENNIUM PHARMACEUTICALS, INC. 40 Landsdowne Street CAMBRIDGE, MA 02139			PATTERSON, CHARLES L JR	
			ART UNIT	PAPER NUMBER
	,		1652	

DATE MAILED: 11/30/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	No. Applicant(s)				
Office Action Summary		10/810,793	CHEN, ZHIJIAN J.				
		Examiner	Art Unit				
		Charles L. Patterson, Jr.	1652				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1)□	Responsive to communication(s) filed on						
		—· s action is non-final.	,				
•	· <u> </u>						
	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4)⊠ Claim(s) <u>7-26</u> is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.						
	5) Claim(s) is/are allowed.						
	6) Claim(s) is/are rejected.						
ا لکا(ہ	8) Claim(s) 7-26 are subject to restriction and/or election requirement.						
Application	on Papers						
9) The specification is objected to by the Examiner.							
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority u	nder 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). 							
Attachment(1) \(\bigcup \) Notice 2) \(\bigcup \) Notice 3) \(\bigcup \) Inform	s) of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) No(s)/Mail Date	4) ☐ Interview Sumr Paper No(s)/Ma					

Application/Control Number: 10/810,793

Art Unit: 1652

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 7-19, drawn to an antibody, a hybridoma producing the antibody, a method of detecting a kinase by using the antibody and a diagnostic kit comprising the antibody, classified in class 435, subclass 7.4 and 356 and class 530, subclass 387.9.
- II. Claims 20-23, drawn to a bioassay for assessing candidate drugs, classified in class 435, subclass 15.
- III. Claims 20-23, drawn to a bioassay for assessing ligands of a kinase or subunit, classified in class 435, subclass 15.
- IV. Claim 24, drawn to a selective inhibitor of a kinase, classified in many classes and subclasses depending upon the identity of the inhibitor.
- V. Claims 25-26, drawn to a treatment of a disease comprising administering an inhibitor of a kinase, classified in many classes and subclasses depending upon the identity of the inhibitor.

The inventions are distinct, each from the other because:

The antibody of Group I, the bioassay of Groups II and III and the inhibitor or Group IV are unrelated and are patentably distinct.

Inventions IV and V are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in a materially different process such as inhibiting the activity of the kinase, unrelated to any disease treatment.

Art Unit: 1652

It is noted that the IDS filed 3/25/04, in addition to PTO-1449 and PTO/SB/08B, there are included 3 pages of PTO-892. This is not a form that can be used by applicants to cite prior art and includes no place for the examiner's initials or signature. Therefore, if applicants wish the reference included on these PTO-892s considered by the examiner, they should submit them on a PTO-1449.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Charles L. Patterson, Jr., PhD, whose telephone number is 571-272-0936. The examiner can normally be reached on Monday - Friday from 7:30 to 4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Charles L. Patterson, Jr.

Primary Examiner Art Unit 1652

Patterson November 15, 2005